Faculty profile

Guillaume Richard-Carpentier

Back to faculty

Assistant ProfessorDepartment of MedicineUniversity of Toronto

Guillaume Richard-Carpentier

Assistant Professor

Department of Medicine

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
9 publications in the last five years, latest in 2026.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?
Clinical lymphoma, myeloma & leukemia · 2026
IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia.
Biomarker research · 2025
High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort
Biomarker Research · 2025 · first author

All 9 publications

9 publications.

What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?

Rajendra A, Smith E, Atenafu EG, Bankar A, Chan S, Davidson M, Gupta V, Minden MD, Perusini MA, Richard-Carpentier G, Schimmer A, Schuh AC, Sibai H, Yee K, Maze D

Clinical lymphoma, myeloma & leukemia2026

DOI: 10.1016/j.clml.2025.10.016 PMID: 41238480

IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia.

Métois A, Bordeleau ME, Theret L, Hajmirza A, Moujaber O, Spinella JF, Chagraoui J, Mayotte N, Boivin I, Audemard É, Aubert L, Lisi V, Khakipoor B, Farah A, Bonneil É, Robert A, Lippens J, Moraitis A, Béliveau F, Feghaly A, Boucher G, Marcotte R, Gendron P, Thibault P, Lemieux S, Richard-Carpentier G, Lavallée VP, Hébert J, Roux PP, Sauvageau G

Biomarker research20255 citationsOpen Access

DOI: 10.1186/s40364-025-00769-z PMID: 40229904

High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort

Guillaume Richard‐Carpentier, François Béliveau, Sandrine Lacoste, Banafsheh Khakipoor, Véronique Lisi, Michael Vladovsky, Miriam Marquis, Jean-François Spinella, Patrick Gendron, Sébastien Lemieux, Vincent‐Philippe Lavallée, Guy Sauvageau, Josée Hébert

Biomarker Research20253 citationsFirst authorOpen Access

DOI: 10.1186/s40364-025-00827-6 PMID: 41131586

Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.

Rajendra A, Smith E, Perusini MA, Tang K, Atenafu EG, Bankar A, Chan S, Davidson MB, Gupta V, Maze D, Minden MD, Richard-Carpentier G, Schimmer AD, Schuh AC, Yee K, Sibai H

Blood cancer journal20251 citationsOpen Access

DOI: 10.1038/s41408-025-01353-2 PMID: 40854875

Immunotherapeutic targeting of surfaceome heterogeneity in AML.

Bordeleau ME, Audemard É, Métois A, Theret L, Lisi V, Farah A, Spinella JF, Chagraoui J, Moujaber O, Aubert L, Khakipoor B, Mallinger L, Boivin I, Mayotte N, Hajmirza A, Bonneil É, Béliveau F, Pfammatter S, Feghaly A, Boucher G, Gendron P, Thibault P, Barabé F, Lemieux S, Richard-Carpentier G, Hébert J, Lavallée VP, Roux PP, Sauvageau G

Cell reports202435 citationsOpen Access

DOI: 10.1016/j.celrep.2024.114260 PMID: 38838225

Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.

Smith E, Atenafu EG, Bankar A, Chan S, Davidson M, Gupta V, Minden MD, Richard-Carpentier G, Schimmer A, Schuh AC, Sibai H, Yee K, Maze D

European journal of haematology2024Open Access

DOI: 10.1111/ejh.14283 PMID: 39113600

Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials.

H Elsayed A, Cao X, Marrero RJ, Nguyen NHK, Wu H, Ni Y, Ribeiro RC, Tobias H, Valk PJ, Béliveau F, Richard-Carpentier G, Hébert J, Zwaan CM, Gamis A, Kolb EA, Aplenc R, Alonzo TA, Meshinchi S, Rubnitz J, Pounds S, Lamba JK

NPJ precision oncology2024

DOI: 10.1038/s41698-024-00643-5 PMID: 39090192

Impact of secondary-type mutations in NPM1 mutated AML.

Zhou Q, Zhao D, Zarif M, Yeung YWT, Richard-Carpentier G, Chang H

European journal of haematology2023

DOI: 10.1111/ejh.13979 PMID: 37165755

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).

Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM

Haematologica2023First author

DOI: 10.3324/haematol.2022.282030 PMID: 36951163

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Guillaume Richard-Carpentier

Research

Latest papers

What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?

IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia.

High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort

Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.

Immunotherapeutic targeting of surfaceome heterogeneity in AML.

Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.

Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials.

Impact of secondary-type mutations in NPM1 mutated AML.

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).

Frequent collaborators

Dawn Maze

Vikas Gupta

Aaron Schimmer

Guy Sauvageau

Mark Minden

Steven Chan

Sébastien Lemieux

Karen Yee

Aniket Bankar

Hassan Sibai

Marta Davidson

Maria Perusini

Philippe Roux

Hong Chang

Frédéric Barabé

Qianghua Zhou